Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Daisuke Minnami
A Prospective Cohort Study to Define the Clinical and Pathological Features of Lung Cancers Harboring HER2 Gene Aberrations (The HER2-CS Study) and a Phase II Study of Trastuzumab Emtansine (Recombinant) in Patients With HER2-positive Non-Small Cell Lung Cancer Who Recurred, Progressed After Standard Chemotherapy, or Were Primarily Refractory to Standard Chemotherapy
Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
Related publications
Loss of HER2 Positivity After Anti-Her2 Chemotherapy in HER2-positive Gastric Cancer Patients: Results of the GASTric Cancer HER2 Reassessment Study 3 (GASTHER3)
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer With Osimertinib
Clinical Cancer Research
Cancer Research
Oncology
Human Epidermal Growth Factor 2 (HER2) Non-Small Cell Lung Cancer (NSCLC) With YVMA Mutation Responsive to Ado-Trastuzumab Emtansine
Journal of Case Reports and Images in Oncology
Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine
Cancer Management and Research
Oncology
To Study the Clinical Improvement With Standard Chemotherapy Regimen in Stage 3 and Stage 4 Non Small Cell Lung Carcinoma Patients
International Journal of Contemporary Medicine, Surgery and Radiology
HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer
Oncotarget
Oncology
A Phase I/Ii Study of Poziotinib Combined With Paclitaxel and Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
P1.01-41 a Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
